Loading clinical trials...
Loading clinical trials...
Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure
Conditions
Interventions
Flumatinib
Locations
1
China
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, China
Start Date
January 1, 2021
Primary Completion Date
May 30, 2023
Completion Date
December 30, 2023
Last Updated
March 16, 2022
NCT05143840
NCT06119269
NCT03459534
NCT03722420
NCT06233890
NCT04126681
Lead Sponsor
Shenzhen Second People's Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions